Graphene Nanotubes Revolutionize Protective Film Technology: Ultrathin, Permanently Conductive PSA

A novel conductive PSA exhibits remarkable transparency and maintains stable electrical conductivity throughout its lifespan.. Graphene nanotubes inside adhesives make it possible to reduce the number of layers, improving cost-efficiency of processing. The new set of properties enabled by nanotubes expands PSA’s standard range of applications, encompassing optical films, flexible displays, and more.

The global market for conductive pressure-sensitive adhesives (PSAs) is forecast to reach $12.5 billion by 2025, driven by wide-ranging applications. To keep growing, the industry has always been on the lookout for solutions for anti-static PSA, without drawbacks such as degradation of conductivity over time, low transparency, or limited flexibility.

OCSiAl’s exceptional graphene nanotube -based solution addresses these issues, ushering in a new era of silicone PSA technology. The user-friendly nanotube dispersion TUBALLTM MATRIX 617 results in excellent electrical conductivity combined with more than 90% transparency in a wide range of peeling-strength PSA films.

The nanotube concentrate can be seamlessly integrated into silicone PSA resins without altering standard mixing processes or equipment. “The recently developed product is a concentrate based on a user-friendly reactive silicone polymer and pre-dispersed TUBALL™ graphene nanotubes specifically designed for silicone PSA systems. It offers an extremely fine quality of nanotube dispersion and is easier to handle in specific applications, notably in a low solid-content systems,” said Ekaterina Gorbunova, Development and Support Leader for Elastomers and Vice President at OCSiAl Group.

Just 0.2% TUBALL™ MATRIX 617 ensures uniform dispersion of conductive particles inside PSA film. This results in a stable surface resistivity of less than 107 Ohm/sq, even after multiple peelings and exposure to high temperatures, which makes it possible to meet strict requirements for stable touch screen operations. In comparison, traditional PSA on conventional polymer primer can only achieve surface resistivity of 1010Ohm/sq, because above this level, it tends to become unstable over time.

The newly developed, permanently conductive silicone PSA formulations reduce the number of layers needed, eliminate the requirement for a primer, and improve cost-efficiency. The outcome is a new generation of fine, flexible, transparent, sensitive films suitable for applications in high demand in electronics, medical devices, the automotive industry, and packaging.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.